ArticleThe Lancet regional health. Western Pacific2025
Mapping the landscape of healthcare-associated infections in China, 2015-2019: a nation-wide observational study.
Article in The Lancet regional health. Western Pacific, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A retrospective analysis of pathogen distribution and antimicrobial resistance trends of bacteria in a tertiary hospital in China, 2021-2025.Frontiers in cellular and infection microbiology · 2026Article
- Application of the quality control circle model to reduce non-conforming surgical instrument packaging and hospital-acquired infection risk: a pilot study.Frontiers in cellular and infection microbiology · 2026Article
- Genomic epidemiology and antimicrobial resistance prevalence ofFrontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Healthcare-associated infections (HAIs), complicated by antimicrobial resistance continue to affect all countries with unprecedented threat, especially for developing countries. Our objective was to explore the epidemiological features, spatiotemporal heterogeneity and associated factors of HAIs and HAI related multi-drug resistant organisms (MDROs) in China. Methods: We used national surveillance data that were collected from 6867 sampled hospitals during 2015-2019 to determine the annual incidence of HAIs, key HAI-related quality indicators and associated factors. Findings: During 2015-2019, total of 4,959,230 HAIs were reported in sampled hospitals in China, with the overall incidence and prevalence estimated as 1.1 and 2.3 per 100 inpatients, which showed decline trend over time. Carbapenem-resistant Interpretation: The study increases the understanding of HAIs and antimicrobial resistance. It highlights high-risk areas of HAIs and MDROs of concern, where targeted measures to continuously enhance management and policies implementation of HAIs are needed. Funding: The Foundation of State Key Laboratory of Pathogen and Biosecurity of China (Grant No. SKLPBS2443) and Infection Prevention and Control Research Project of "Gan·Dong China" (Grant No. GY2023022-A).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.